

HR 6832

To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 25, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 28, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/6832>

Sponsor

Name: Rep. Cloud, Michael [R-TX-27]

Party: Republican • **State:** TX • **Chamber:** House

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Biggs, Andy [R-AZ-5]	R · AZ		Feb 25, 2022
Rep. Donalds, Byron [R-FL-19]	R · FL		Feb 25, 2022
Rep. Miller, Mary E. [R-IL-15]	R · IL		Feb 25, 2022
Rep. Tiffany, Thomas P. [R-WI-7]	R · WI		Feb 25, 2022
Rep. Webster, Daniel [R-FL-11]	R · FL		Feb 25, 2022
Rep. Brooks, Mo [R-AL-5]	R · AL		Feb 28, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 28, 2022
Financial Services Committee	House	Referred To	Feb 25, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 3440	Identical bill	Jan 4, 2022: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.

This bill restricts various presidential and federal authorities related to the acquisition of supplies to combat COVID-19.

Specifically, the bill prohibits the President from exercising certain authorities under the Defense Production Act of 1950 to prioritize the performance of federal contracts or orders for COVID-19 supplies over the performance of state or territorial contracts or orders. In addition, states or territories may use federal COVID-19 relief funds for COVID-19 supplies that they had been unable to purchase because of prioritized performance of federal contracts or orders. (The Defense Production Act of 1950 confers upon the President a broad set of authorities to influence domestic industry in order to provide essential materials and goods needed for the national defense.)

Additionally, the Food and Drug Administration may not ration, limit, restrict access to, or otherwise control the quantity of a medical product authorized for use during an emergency, including by requiring products to be distributed through a state- or territorial-based system.

Actions Timeline

- **Feb 28, 2022:** Referred to the Subcommittee on Health.
- **Feb 25, 2022:** Introduced in House
- **Feb 25, 2022:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.